CRI Logo
  • About
    • Impact
    • History
    • Team
    • Careers
    • Blog
    • Media Room
  • What is Immunotherapy?
    • Immunotherapy Basics
    • Treatment Types
    • Cancer Types
    • Side Effects
  • Patient Support
    • Patient Resources
    • Clinical Trials
    • Immunotherapy Stories
    • Connect with ImmunoAdvocates
  • Grants & Research Programs
    • Apply for Grants
    • Research Programs
    • Clinical Programs
    • Data Programs
    • CRI Funded Scientists
  • Get Involved
    • Ways to give
    • Fundraise
    • Events
    • Partnership
    • Contact
Donate

Immune to Cancer: The CRI Blog

  • Dr. Robert Schreiber and Interferon Gamma

    By redefining our understanding of the relationship between cancer and the immune system, Dr. Robert Schreiber has…

    May 16, 2019| Arthur N. Brodsky, PhD
  • AACR19 Recap: Leveraging the Latest Science to Improve Clinical Care

    AACR19 highlighted incredible advances in our efforts to leverage cutting-edge science in order to improve medical treatment for…

    April 5, 2019| Arthur N. Brodsky, PhD
  • CRI-Funded Trial Reveals Promising Potential of Immunotherapy Combination in Metastatic Pancreatic Cancer

    Interim data from a novel immunotherapy-chemotherapy combination that targets the CD40 and PD-1 pathways show promising anti-tumor…

    March 31, 2019| Arthur N. Brodsky, PhD
  • IO360 2019 Preview: Collaboration, Investment, Clinical Trials, and Combinations

    The fifth annual Immuno-Oncology 360° conference will be held on February 6-8, 2019 in New York City.

    February 1, 2019| Arthur N. Brodsky, PhD
  • How Immunotherapy Is Making an Impact in Liver Cancer

    We spoke with Bruno Sangro, MD, PhD, about the current treatment landscape for patients with liver cancer,…

    December 21, 2018| Arthur N. Brodsky, PhD
  • Recapping the Third Annual Rational Combinations 360°

    In September, experts across the immunology and immunotherapy spectrum convened in Philadelphia to discuss the latest advances…

    September 17, 2018| Arthur N. Brodsky, PhD
  • 30 Days of CRI Impact

    Throughout Cancer Immunotherapy Month in June we’ll be highlighting the 30 most important CRI-funded breakthroughs.

    June 1, 2018| Arthur N. Brodsky, PhD
  • Second CAR T Cell Immunotherapy Approved for Patients with Lymphoma

    A second CAR T cell immunotherapy targeting the CD19 receptor was approved by the FDA for patients…

    May 3, 2018| Arthur N. Brodsky, PhD
  • Advocating for Innovative Clinical Trial Design

    Laura Pearce, CRI consultant and head of clinical alliances, participates in a clinical trials panel on platform…

    April 25, 2018| Katherine McCluskey
Previous Page
1 … 7 8 9 10 11 12
Next Page

Cancer Research Institute
29 Broadway, Floor 4

New York, NY  10006-3111

Facebook Icon
X icon
YouTube icon
LinkedIn icon
Instagram icon
Threads icon
  • About
    • Impact
    • History
    • Team
    • Careers
    • Blog
    • Media Room
  • What is Immunotherapy?
    • Immunotherapy Basics
    • Treatment Type
    • Cancer Type
    • Side Effects
  • Patient Support
    • Patient Resources
    • Clinical Trials
    • Immunotherapy Stories
    • Connect with ImmunoAdvocates
  • Grants & Research Programs
    • Apply for Grants
    • Research Programs
    • Clinical Programs
    • Data Programs
    • CRI Funded Scientists
  • Get Involved
    • Donate
    • Ways to give
    • Fundraise
    • Events
    • Partnership
    • Contact

Uniting for a World Immune to Cancer

  • Accessibility Statement
  • Privacy Policy
  • Terms & Conditions
  • Site Map

*Immunotherapy results may vary from patient to patient.

©2025, Cancer Research Institute